文献速递淋巴瘤

滤泡性淋巴瘤:2020年诊断与管理更新

Follicular lymphoma: 2020 update on diagnosis and management.
PubMed 文献 · Am J Hematol · 2019-12-22

滤泡性淋巴瘤(FL)是一种惰性B细胞淋巴增殖性疾病,以弥漫性淋巴结病、骨髓受累和脾肿大为特征。诊断基于淋巴结或其他受累组织的活检组织学,免疫组化几乎均表达CD19、CD20、CD10和单克隆免疫球蛋白,以及bcl-2蛋白。FLIPI风险分层使用五个独立预测因素。无症状低肿瘤负荷且无血细胞减少的患者适合观察,需要治疗者多采用化学免疫治疗,维持利妥昔单抗有额外获益。

要点

  • 诊断依赖切除活检组织学,免疫组化CD19、CD20、CD10阳性及bcl-2表达。
  • FLIPI风险分层:年龄>60岁、血红蛋白<12 g/dL、LDH>正常、III/IV期、淋巴结区域>4个。
  • 无症状低肿瘤负荷无血细胞减少者可观察,早期治疗无总生存获益。

核心结论

  • 滤泡性淋巴瘤为惰性B细胞淋巴增殖性疾病,现代治疗已明显改善预后。
  • 无症状低肿瘤负荷且无血细胞减少的患者适合观察,早期治疗无总生存优势。

研究设计与样本

  • 综述,基于2020年更新的诊断与管理证据。

主要发现

  • FL以弥漫性淋巴结病、骨髓受累和脾肿大为特征,结外受累较少见。
  • 免疫组化几乎均表达CD19、CD20、CD10和单克隆免疫球蛋白,以及bcl-2蛋白。
  • 绝大多数病例具有特征性t(14;18)易位涉及IgH/bcl-2基因。
  • FLIPI使用年龄>60岁、血红蛋白<12 g/dL、血清LDH>正常、Ann Arbor III/IV期、受累淋巴结区域>4个五个独立预测因素。
  • 0-1、2和≥3个不良因素分别定义低、中、高风险疾病。

关键数值与推荐

  • FLIPI风险分层:0-1个不良因素为低危,2个为中危,≥3个为高危。
  • 化学免疫治疗改善缓解率、缓解持续时间和总生存。
  • 随机研究显示维持利妥昔单抗有额外获益。
  • 来那度胺在一线随机研究中非劣于化学免疫治疗,与利妥昔单抗联合在复发FL中优于利妥昔单抗单药。

临床怎么用

  • 无症状低肿瘤负荷且无血细胞减少的FL患者可观察。
  • 需要治疗的患者多采用化学免疫治疗,可考虑维持利妥昔单抗。
  • 复发疾病可考虑激酶抑制剂、其他免疫治疗和干细胞移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is characterized by diffuse lymphadenopathy, bone marrow involvement, and splenomegaly. Extranodal involvement is less common. Cytopenias are relatively common but constitutional symptoms of fever, night sweats, and weight loss are uncommon in the absence of transformation to diffuse large B cell lymphoma. DIAGNOSIS: The diagnosis is based on histology from a biopsy of a lymph node or other affected tissue. Incisional biopsy is preferred over needle biopsies in order to give adequate tissue to assign grade and assess for transformation. Immunohistochemical staining is positive in virtually all cases for cell surface CD19, CD20, CD10 and monoclonal immunoglobulin, as well as cytoplasmic expression of bcl-2 protein. The overwhelming majority of cases have the characteristic t(14;18) translocation involving the IgH/bcl-2 genes. RISK STRATIFICATION: The Follicular Lymphoma International Prognostic Index (FLIPI) uses five independent predictors of inferior survival: age > 60 years, hemoglobin <12 g/dL, serum LDH > normal, Ann Arbor stage III/IV, number of involved nodal areas >4. The presence of 0-1, 2, and ≥ 3 adverse factors defines low, intermediate, and high-risk disease. There are other clinical prognostic models but the FLIPI remains the most common. Other factors such as time to relapse of less than 2 years from chemoimmunotherapy and specific gene mutations may also be useful for prognosis. Regardless of the prognostic model used, modern therapies have demonstrably improved prognosis. RISK-ADAPTED THERAPY: Observation continues to be appropriate for asymptomatic patients with low bulk disease and no cytopenias. There is no overall survival advantage for early treatment with either chemotherapy or single agent rituximab. For patients needing therapy, most patients are treated with chemoimmunotherapy, which has improved response rates, duration of response and overall survival (OS). Randomized studies have shown additional benefit for maintenance rituximab. Lenalidomide was non-inferior to chemoimmunotherapy in a randomized front-line study and, when combined with rituximab, was superior to rituximab alone in relapsed FL. Kinase inhibitors, other immunotherapies, and stem cell transplantation (SCT) are also considered for recurrent disease.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2019. PMID: 31814159. doi:10.1002/ajh.25696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。